Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
good buying here imv.... not advice!!!
Craneware: Investec moves target price from 475p to 410p and stays with its hold rating. Numis upgrades to hold with its target price still at 405p. N+1 Singer ups target price from 365p to 425p retaining its buy recommendation.
"Fiscal and regulatory pressures on US hospitals, including the recently announced expansion of the Medicare Recovery Audit Contractor Programme, continues to drive interest in our suite of software solutions and we are confident in the ongoing strength of our position within this growing area of the US healthcare market."
US healthcare software developer Craneware said first half trading has been positive as increased levels of sales start to contribute to revenue growth. The group, which provides monitoring and automated revenue systems, said it expects to report revenue growth to $20.1m, up from $18.8m in the same half in 2012 with further growth at the adjusted EBITDA level of around 15% from the same period last year. Craneware said this performance is in line with management's expectations, "delivering similar first half to second half expectation splits as those seen in the previous financial year." CEO Keith Neilson commented, "The increased levels of sales activity discussed at the time of our final results in September 2012 have begun to contribute to revenue growth."
highly undervalued stock fallen recently for no reason from 4.80..Good trading update today. The regulations for hospitals increasing in USA , this stock is due for a strong re-rating and won't be long before it's above the 6.00 level. A chance takeover from across the pond , can not be ruled out. Strong BUY!!
Keith Neilson, CEO of Craneware,commented, "The increased levels of sales activity discussed at the time of our final results in September 2012 have begun to contribute to revenue growth. Fiscal and regulatory pressures on US hospitals, including the recently announced expansion of the Medicare Recovery Audit Contractor Program, continues to drive interest in our suite of software solutions and we are confident in the ongoing strength of our position within this growing area of the US healthcare market."
Trading Update 21 January 2013 - Craneware(AIM: CRW.L), the market leader in automated revenue integrity solutions for the US healthcare market, provides an update on trading for the six month period ended 31 December 2012. Trading has been positive in the first half of the financial year and the Company expects to report revenue growth to $20.1m (H112: $18.8m) with further growth at the adjusted EBITDA level of approximately 15% in comparison to the same period in the prior year (H112: $4.65m). This performance is in line with management's expectations, delivering similar first half to second half expectation splits as those seen in the previous financial year.
perhaps
may I have some at 3.25p ?
DYOR/not investment advice, but EV probably not much greater than 10X plausible next year op profit (based on simple extrapolation/nothing more sophisticated so take with huge dollop of salt)
Craneware: Investec raises target price from 410p to 475p and downgrades from buy to hold.
You could be your own doctor But while these represent ways of making administration more efficient, technology can also radically alter our approach to healthcare. There are high hopes for remote patient monitoring. A range of devices are now available that enable a patient to monitor his own condition and then send this to his doctor.
CRANEWARE (CRW) has made a highly successful business by simplifying the production of treatment invoices in the United States. Patient records are another focus of health authorities. It has proved rather difficult for the NHS to convert its paper patient records to digital format. This should have been a relatively straightforward task. But the future is surely electronic records, where they are accessible anytime, anywhere – including, for example, via your doctor’s laptop when he pays you a visit.
Craneware sees return to double digit revenue growth Keith Neilson CEO and Co-founder of Craneware (LON:CRW) tells Proactiveinvestors that opportunities exist for the company to broaden out and, as a consequence,he hopes to see the return of double digit revenue growth. With long term multi-year contracts Keith says that Craneware is in a "good position in US healthcare" with the government there spending roughly $3tln per annum http://www.proactiveinvestors.co.uk/companies/stocktube/1357/craneware-sees-return-to-double-digit-revenue-growth-1357.html
sorry to be a rolling stone, but will still keep an eye on this and maybe back for more. like to get out on double tops.
Buzle - absolutely - well played.
you get what you need! profits a profit don't know where to next but out for now till I get a bit more direction
If you try sometimes. . . .
You don't always get what you want
You don't always get what you want
You don't always get what you want
buzle - 345 is good - if we all got that mark up each time we traded we would all be smiling big time..
a little late though by the time i'd worked out what i was going to do, crw had busted through 340 (resistance) so, I took a smaller stake than i wanted at 345 (to limit risk). Still ... up is good.
* dip a toe, not did a toe!